PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Pelthos Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$20.26+0.11 (+0.55%)

Close on Oct 19, 2026

Market cap: $71.71M
P/E (TTM): –
Dividend yield: –

Pelthos Therapeutics Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	17	0	–	–
Cost of Revenue	3.99	0	–	–
Gross Profit	13	0	–	–
Research & Development	1.23	1.18	2.58	0.39
Selling, General & Admin	42	6.39	–	–
General & Administrative	–	4.11	2.74	1.10
Operating Expenses	–	7.57	6.86	2.32
Total Costs & Expenses	49	7.57	–	–
Operating Income	-32	-7.57	-6.86	-2.32
Interest Expense	3.01	0.79	0.31	0.14
Other Non-Operating Income	-18	-0.38	-0.52	-0.14
Legal Settlements	0	0.36	–	–
Pretax Income	-51	-7.96	-7.38	-2.46
Income Tax Expense	-7.39	0	–	–
Net Income	-43	-7.96	-7.38	-2.46
EPS (Basic)(per share)	-23.04	-14.27	-57.80	56.50
EPS (Diluted)(per share)	-23.04	-14.27	-57.80	–
Shares Outstanding (Basic, Weighted)(shares)	1.88	0.56	0.13	0.04
Shares Outstanding (Diluted, Weighted)(shares)	1.88	0.56	0.13	0.04

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 78.6%
Operating margin: -133.4%
Net margin: -199.5%
Return on equity, FY2025: -239.5%

Financial strength

Current ratio: 1.98
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 75.7%

Valuation

P/E ratio: –
Price to sales: 1.66
Price to book: –
Dividend yield: –